Zydus Life Net Profit soars 31% in Q1FY25, posts highest ever EBIDTA
Zydus Lifesciences Limited announced its unaudited consolidated financial results for the first quarter ended June 30th, 2024.
| Rs. mn | Q1
FY25 |
Q1
FY24 |
% Gr. YoY |
Q4
FY24 |
% Gr. QoQ |
| Revenue from operations | 62,075 | 51,396 | 20.8% | 55,338 | 12.2% |
| EBITDA | 20,840 | 15,053 | 38.4% | 16,305 | 27.8% |
| EBITDA margin (%) | 33.6% | 29.3% | 29.5% | ||
| PBT | 18,997 | 13,292 | 42.9% | 15,470 | 22.8% |
| Net Profit | 14,199 | 10,869 | 30.6% | 11,823 | 20.1% |
- Revenue from operations at Rs. 62,075 mn, up 21% YoY.
- Research & Development (R&D) investments for the quarter stood at Rs. 3,925 mn (6.3% of revenues).
- EBITDA for the quarter was Rs. 20,840 mn, up 38% YoY. EBITDA margin for the quarter stood at 33.6% which is an improvement of 430 bps on a YoY basis.
- Net Profit for the quarter was Rs. 14,199 mn, up 31% YoY.
- Capex (organic) for the quarter was Rs. 3,014 mn.
